Trial Profile
Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FOCUS
- Sponsors Biogen
- 01 Jun 2019 Primary endpoint (Change in the number of new or newly enlarging T2 hyperintense lesions on brain MRI scans from the Baseline Period to On-Treatment Assessment Period) has been met.
- 02 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016.
- 02 Aug 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2016.